Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-cell profiling reveals diverse γδ T cell subsets in ulcerative colitis.

Science immunology·2026
Same author

Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer.

International journal of molecular sciences·2024
Same author

Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice.

International journal of molecular sciences·2023
Same author

Basal-like mammary carcinomas stimulate cancer stem cell properties through AXL-signaling to induce chemotherapy resistance.

International journal of cancer·2023
Same author

Isolation of Hepatocytes from Liver Tissue by a Novel, Semi-Automated Perfusion Technology.

Biomedicines·2022

Related Experiment Video

Updated: Jan 15, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K

Triple-Negative Breast Cancer Unveiled: Bridging Science, Treatment Strategy, and Economic Aspects.

Valeriia Lebedeva1,2, Mira Ebbinghaus1, José Villacorta Hidalgo1

  • 1Research and Development Department, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.

International Journal of Molecular Sciences
|October 16, 2025
PubMed
Summary

Triple-negative breast cancer (TNBC) treatment has advanced with new therapies, but challenges like heterogeneity and cost limit patient benefit. Global collaboration and patient-centered care are crucial for future drug development.

Keywords:
health care accesshealth care economicsprecision therapiestargeted therapiestriple-negative breast cancer

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.7K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Related Experiment Videos

Last Updated: Jan 15, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.7K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Area of Science:

  • Oncology
  • Pharmacology
  • Health Economics

Background:

  • Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to its heterogeneity and limited treatment options.
  • Recent approvals of precision therapies like immune checkpoint inhibitors and PARP inhibitors have improved outcomes but not universally.
  • Variable patient responses and high drug costs impact real-world effectiveness, especially in low- and middle-income countries.

Purpose of the Study:

  • To provide a comprehensive review of current TNBC management strategies.
  • To integrate clinical advancements with economic considerations in TNBC treatment.
  • To highlight unmet needs and future directions in TNBC drug development.

Main Methods:

  • Literature review of recent clinical trials and therapeutic approvals for TNBC.
  • Analysis of economic factors influencing TNBC treatment accessibility and cost-effectiveness.
  • Synthesis of data to identify challenges and opportunities in TNBC management.

Main Results:

  • Despite progress, TNBC heterogeneity and drug-tumor interactions limit treatment efficacy and patient eligibility.
  • Emerging TNBC drugs show variable outcomes, and high costs pose a significant barrier, particularly in resource-limited settings.
  • Existing treatments often provide insufficient clinical benefit relative to their high expenditure.

Conclusions:

  • A global, interdisciplinary approach is essential for advancing TNBC drug development.
  • Patient-centered care and improved access to effective therapies are critical for addressing the TNBC burden.
  • Further research is needed to understand TNBC heterogeneity and optimize treatment strategies for diverse populations.